Stelerix Web Blog Knowledge at your Fingertips


Healthcare Cost Containment in Europe

The scenario is somewhat bleak, or at least that's what Ulf Staginnus, Head of health economics in Europe at Novartis Oncology had to say.

We'll have the whole interview up on the main site, shortly. For now, enjoy this:

Best regards,



Monday Morning

We are moving pretty quickly this morning, although another cup of extra hot coffee might be called for, shortly. But before we do, check out these headlines...

Respondents have always been clear that while the domestic Indian market needs to continue to grow and mature, especially with regards to infrastructure, it is a great place from which to access other emerging markets. Ranbaxy proves this hypothesis in South Africa with a successful bid to supply $133 million wort of anti-retroviral (ARV) drugs.

We have been very curious about the recent and ongoing M&A activity in India. Emami lost it's bid last week for Paras Pharmaceutical, but it's coffers are still stuffed with cash and analysts are bullish on the idea that they will snap up something else, perhaps in the consumer goods or food sectors.

Although Novartis dedicated one sentence to BRIC markets in it's annual long term strategic outlook, the money says a lot more. Novartis commits to a full scale pharmaceutical facility in Russia as part of a $500 million investment.

Enjoy this week and the ensuing holiday!

Posted by Jeff